非小细胞肺癌化疗中的程序性死亡？ - Suppr

Suppr

超能文献

Programmed death of chemotherapy in non-small-cell lung cancer?

作者信息

Leduc Charlotte, Quoix Elisabeth

机构信息

Department of Pneumology, University Hospital, Strasbourg, France.

出版信息

Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1. Epub 2016 Dec 13.

DOI:10.1016/S0140-6736(16)32535-1

PMID:27979385

Abstract

摘要

相似文献

Programmed death of chemotherapy in non-small-cell lung cancer?

Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1. Epub 2016 Dec 13.

Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.

J Clin Oncol. 2016 Sep 1;34(25):2953-5. doi: 10.1200/JCO.2016.68.1205. Epub 2016 Jul 5.

[The predicive biomarkers of programmed death receptor-l/ligand antibodes in the treatement of non-small-cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi. 2018 Oct 12;41(10):799-803. doi: 10.3760/cma.j.issn.1001-0939.2018.10.010.

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.

J Thorac Oncol. 2018 Apr;13(4):e55-e56. doi: 10.1016/j.jtho.2017.11.113.

Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".

J Thorac Oncol. 2018 Apr;13(4):e56-e57. doi: 10.1016/j.jtho.2017.11.122.

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.

Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.

Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.

J Thorac Oncol. 2018 Jun;13(6):741-744. doi: 10.1016/j.jtho.2018.04.008.

Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?

J Thorac Oncol. 2018 Apr;13(4):475-477. doi: 10.1016/j.jtho.2018.02.019.

Analysis of the association between adverse events and outcome in patients receiving a programmed death protein-1 or programmed death ligand-1 antibody.

Chin Clin Oncol. 2020 Aug;9(4):57. doi: 10.21037/cco.2020.03.01. Epub 2020 Mar 4.

Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer.

Lancet Oncol. 2019 Oct;20(10):1334-1335. doi: 10.1016/S1470-2045(19)30508-X. Epub 2019 Aug 14.

引用本文的文献

#2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models.

Cell Death Discov. 2018 Feb 14;4:24. doi: 10.1038/s41420-018-0032-y. eCollection 2018 Dec.

SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis.

Front Pharmacol. 2018 Jan 4;8:960. doi: 10.3389/fphar.2017.00960. eCollection 2017.

A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.

J Thorac Dis. 2017 Mar;9(3):E292-E294. doi: 10.21037/jtd.2017.02.86.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验